phase 1 study of crizotinib in patients with alk-positive non-small cell lung cancer
Published 13 years ago • 1K plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
13:28
debate: alk positive nsclc - front line therapy - crizotinib
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
3:53
how to maximize clinical benefits for patients with alk-positive non-small cell lung cancer
-
4:10
crizotinib resistance in alk nsclc
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:22
dr. crinò on crizotinib in alk nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
5:28
crown study: lorlatinib vs crizotinib in 1l nsclc
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
6:04
case study: progression on alk inhibitors in nsclc
-
0:58
progress in the treatment of alk-positive non-small cell lung cancer
-
4:00
alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
22:10
first and second generation alk inhibitors for the treatment of lung cancer
-
1:01
targeting alk rearrangements in non-small cell lung cancer